The first domestic CD38/CD3 double anti-declaration clinical.

CD38 is a widely expressed transmembrane glycoprotein, clinically proven to be a therapeutic target for multiple myeloma.
the expression level of CD38 on the surface of pulp cells and malignant multiple myeloma cancer cells is high.
Youchiyou biological website shows that Y150 uses the independent innovation of YBODY ® platform technology, one end targets the high expression of tumor cells CD38 antigen, the other end targets the immune T cell surface CD3 antigen.
inhibit tumor cell growth by targeting CD38 antigens and CD3 antigens, recruiting T cells to tumor cells and activating T cells to immune tumor cells.
multiple myeloma (MM) is a malignant proliferative tumor that is the source of plasma cells. The main pathological characteristics of
are the abnormal proliferation of plasma cells in the bone marrow, the secretion of monoclonal immunoglobulin or its fragments (M protein), resulting in tissue and organ damage. there is no cure
MM.
the clinical use of drugs such as thalidomide, linadoamine, boronyzomi and CD38 monototama has greatly increased the rate of MM remission in recent years, and the recurrence caused by micro-residual lesions (MRD) cannot be completely avoided. Patients
patients whose diseases are still progressing after treatment with thalidomide, linamine, boratizomi and CD38 monototama, face a situation where no medicine is available.
Y150 is working to develop a clinical drug for patients with multiple myeloma who are still progressing after treatment with thalidomide, linadoamine, boratizomi and CD38 monototama.
compared with foreign monotonoids, has the advantages of good efficacy, not easy to produce drug resistance, small dose of medicine.
.